Loading company…
Sequenta developed immune-based diagnostics for detecting minimal residual disease in blood cancers.
Founded in 2008, Sequenta developed immune-based diagnostic solutions using the adaptive immune system. Its clonoSEQ® product uses sequencing to assess minimal residual disease in hematological malignancies. The company was based in South San Francisco, US, and was acquired by Adaptive Biotechnologies in January 2015.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in